Dupilumab Monthly Dose De-Escalation Maintains Efficacy in CRSwNP January 9, 2026 Does extending dupilumab dosing from every two weeks to every four weeks maintain clinical efficacy in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP)?